Stelazine

Schizophrenia, Alzheimer's Disease, Agitation + 2 more
Treatment
2 FDA approvals
20 Active Studies for Stelazine

What is Stelazine

TrifluoperazineThe Generic name of this drug
Treatment SummaryProchlorperazine is a medication used to treat psychotic symptoms (such as hallucinations and delusions) and to reduce nausea and vomiting. It is a type of phenothiazine, similar to the drug chlorpromazine, and works by blocking certain types of receptors in the brain.
Trifluoperazine Hydrochlorideis the brand name
image of different drug pills on a surface
Stelazine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Trifluoperazine Hydrochloride
Trifluoperazine
1981
36

Approved as Treatment by the FDA

Trifluoperazine, otherwise called Trifluoperazine Hydrochloride, is approved by the FDA for 2 uses such as Anxiety and Schizophrenia .
Anxiety
Helps manage acute non-psychotic Anxiety
Schizophrenia
Helps manage Schizophrenia

Effectiveness

How Stelazine Affects PatientsTrifluoperazine is a type of drug used to treat schizophrenia and other mental health conditions. It has not been found to be helpful in treating behavioral issues in people with intellectual disabilities.
How Stelazine works in the bodyTrifluoperazine affects the chemical balance in the brain by blocking certain dopamine receptors. It also decreases the release of hormones from the hypothalamus and pituitary glands, which can affect your metabolism, body temperature, alertness, blood pressure, and vomiting.

When to interrupt dosage

The quantity of Stelazine is subject to the diagnosed affliction, such as Agitation, Anxiety and Alzheimer's Disease. The dosage changes, contingent upon the delivery technique (e.g. Tablet, film coated - Oral or Oral) detailed in the table beneath.
Condition
Dosage
Administration
Alzheimer's Disease
1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL
Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup, Syrup - Oral
Schizophrenia
1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL
Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup, Syrup - Oral
Agitation
1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL
Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup, Syrup - Oral
Schizophrenia
1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL
Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup, Syrup - Oral
Anxiety
1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL
Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup, Syrup - Oral

Warnings

Stelazine has five contraindications and should not be administered when suffering from any of the conditions laid out in the table below.Stelazine Contraindications
Condition
Risk Level
Notes
Coma
Do Not Combine
preexisting liver damage
Do Not Combine
Bone Marrow
Do Not Combine
greatly depression
Do Not Combine
existing blood dyscrasias
Do Not Combine
There are 20 known major drug interactions with Stelazine.
Common Stelazine Drug Interactions
Drug Name
Risk Level
Description
Acepromazine
Major
Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Alfuzosin
Major
Trifluoperazine may increase the hypotensive activities of Alfuzosin.
Amisulpride
Major
Trifluoperazine may increase the antipsychotic activities of Amisulpride.
Aripiprazole
Major
Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Aripiprazole lauroxil
Major
Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.
Stelazine Toxicity & Overdose RiskThe symptoms of an overdose on Atenolol may include agitation, loss of consciousness, seizures, difficulty breathing or swallowing, dry mouth, excessive drowsiness, fever, blocked intestines, abnormal heart rate, low blood pressure, and restlessness.

Stelazine Novel Uses: Which Conditions Have a Clinical Trial Featuring Stelazine?

453 active studies are being conducted to appraise the effectiveness of Stelazine in treating Anxiety, Agitation and Schizophrenic symptoms.
Condition
Clinical Trials
Trial Phases
Schizophrenia
97 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
Alzheimer's Disease
112 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1
Schizophrenia
31 Actively Recruiting
Early Phase 1, Not Applicable, Phase 4
Agitation
3 Actively Recruiting
Phase 2, Phase 3, Not Applicable
Anxiety
0 Actively Recruiting

Stelazine Reviews: What are patients saying about Stelazine?

5Patient Review
6/19/2010
Stelazine for Mental Disorder with Loss of Normal Personality & Reality
This medication has been a life-saver for me. It's allowed me to think clearly and be myself again.
5Patient Review
9/27/2018
Stelazine for Mental Disorder with Loss of Normal Personality & Reality
This treatment was great! It helped me a lot.
5Patient Review
3/15/2010
Stelazine for Schizophrenia
Olanzapine 10mgs a day Mirtazapine Zopiclone 15 mgs nocte
4Patient Review
1/20/2011
Stelazine for Mental Disorder with Loss of Normal Personality & Reality
Stelazine 4mg was really effective when other treatments didn't work for my bipolar disorder. I don't love the side effects (tremors and loss of libido) but they're manageable.
4Patient Review
9/13/2012
Stelazine for Anxious
This drug was effective for me.
3Patient Review
7/14/2014
Stelazine for Anxious
I felt pretty sedated and tired after taking this, and experienced some dizziness.
1Patient Review
7/15/2009
Stelazine for Mental Disorder with Loss of Normal Personality & Reality
This treatment is ineffective and dangerous. It's like treating asthma with Zyklon B.
1Patient Review
8/21/2008
Stelazine for Mental Disorder with Loss of Normal Personality & Reality
1Patient Review
1/9/2010
Stelazine for Anxious
I was on a 5 mg dose of this drug for 8 years, and then my neurologist put me on Risperdal 2 mg for 18 years. He said that this contributed to my development of Parkinson's disease.

Patient Q&A Section about stelazine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Stelazine used for?

"It can also reduce unwanted/uncontrolled movements (such as twitching, fidgeting, muscle stiffness).

Trifluoperazine is used for treating mental/mood disorders such as schizophrenia and psychotic disorders. It can help patients think more clearly, feel less nervous, and take part in everyday life. Trifluoperazine can also reduce aggressive behavior, the desire to hurt oneself/others, and unwanted/uncontrolled movements (such as twitching, fidgeting, and muscle stiffness)."

Answered by AI

How long can you take Stelazine?

"Stelazine (trifluoperazine) should not be used to treat non-psychotic anxiety at doses higher than 6 mg per day or for longer than 12 weeks. Higher doses or longer intervals of use may cause persistent tardive dyskinesia."

Answered by AI

Why is Stelazine discontinued?

"Trifluoperazine can cause extrapyramidal side effects, which are abnormal muscle contractions, difficulty breathing and swallowing, and neck spasms."

Answered by AI

Is Stelazine still available?

"Stelazine is no longer available as a brand-name medication. It can only be found in generic form."

Answered by AI

Clinical Trials for Stelazine

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Multimodal Intervention for Bipolar Disorder

18 - 35
All Sexes
Hamilton, Canada
People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment. Although clinical guidelines recommend combining medication and psychosocial support, and research shows that early intervention is associated with improved outcomes, no structured care programs currently exist for individuals in the early stages of BD, contributing to chronic illness progression and preventable hospitalizations. This open-label pilot trial will assess the feasibility, acceptability, and preliminary effectiveness of a structured care pathway to support the transition from hospital to community care. The intervention includes group-based psychoeducation, individual peer support, and personalized support for community healthcare providers to improve illness insight, treatment adherence, and symptom management.
Waitlist Available
Has No Placebo
St. Joseph's Healthcare Hamilton
Have you considered Stelazine clinical trials? We made a collection of clinical trials featuring Stelazine, we think they might fit your search criteria.Go to Trials
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Brain Stimulation for Cannabis Craving in Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder. This is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis. Aim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100). Aim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100). As an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric Hospital
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric HospitalHeather Ward, MD
Have you considered Stelazine clinical trials? We made a collection of clinical trials featuring Stelazine, we think they might fit your search criteria.Go to Trials
Image of HealthPartners Neuroscience Center in Saint Paul, United States.

Insole and Ankle Device for Dementia

18+
All Sexes
Saint Paul, MN
This study tests an innovative system and service for collecting objective, consistent, and in-community gait parameters suitable for use as AD/ADRD biomarkers. The system is designed to be affordable, scalable, and practical for longitudinal, unsupervised, in-community use by older adults, including those with dementia symptoms. This study will be performed in two parts and involves collecting gait data from participants using the leg module and insole device either (1) for several hours in a lab setting (in-lab testing) or (2) within their home and community for 1 week (in-community testing). Thirty people who are healthy, have mild cognitive impairment, or who have Alzheimer's disease or related dementia will be recruited to participate in the in-lab testing, in which they will perform walking tasks and cognitive testing for several hours within a lab environment. After completion of in-lab testing, 120 individuals who are healthy, have mild cognitive impairment, or who have Alzheimer's disease or related dementia will be recruited to participate in the in-community testing, in which they will wear the insole and ankle device within their community for 1-week for collection of gait data in real world settings.
Waitlist Available
Has No Placebo
HealthPartners Neuroscience CenterInnovative Design Labs
Have you considered Stelazine clinical trials? We made a collection of clinical trials featuring Stelazine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security